TED Ted Baker Plc

 

TIDMTED 
 
RNS Number : 6361O 
Tepnel Life Sciences PLC 
10 March 2009 
 

 
 
 
 
Tepnel Life Sciences plc ('Tepnel' or 'the Company') 
 
 
Exercise of Warrants and Options 
 
 
 
 
Manchester, UK, 10 March 2009: Tepnel Life Sciences PLC (AIM: TED), the 
international Molecular Diagnostics and Research Products & Services group, 
today announces that the Board of Directors approved the issue of 5,219,444 new 
Ordinary Shares of 1 pence each in connection with the exercise of warrants and 
options as detailed below: 
 
 
+-----------------------------+------------------------+ 
| Warrants                                             | 
+------------------------------------------------------+ 
| Number                      | Exercise Price (pence) | 
+-----------------------------+------------------------+ 
| 4,420,000                   | 6.98                   | 
+-----------------------------+------------------------+ 
| 523,444                     | 8.05                   | 
+-----------------------------+------------------------+ 
 
+-----------------------------+------------------------+ 
| Options                                              | 
+------------------------------------------------------+ 
| Number                      | Exercise Price (pence) | 
+-----------------------------+------------------------+ 
| 238,000                     | 6.125                  | 
+-----------------------------+------------------------+ 
| 35,000                      | 8                      | 
+-----------------------------+------------------------+ 
| 3,000                       | 22                     | 
+-----------------------------+------------------------+ 
 
 
 
 
 
Application has been made by the Company for the 5,219,444 new Ordinary Shares 
to be admitted to the AIM market. It is expected that Admission will become 
effective and that dealings on AIM will commence on or around 16 March 2009. 
 
 
Following admission to AIM of the new Ordinary Shares, the total number of 
Ordinary Shares in issue will be 249,180,970. 
 
 
-End- 
 
 
For further information: 
 
 
Tepnel Life Sciences plc 
Ben Matzilevich, CEO 
Michael Slater, Group Finance Director 
Carol Smith, Group Marketing Communications Manager 
Tel: 0161 946 2200 
 
 
Capital MS&L 
Mary Clark or Catie Corcoran 
Tel: +44 20 7307 5330 
 
 
Seymour Pierce Limited 
Mark Percy 
Tom Sheldon 
Christopher Wren 
Tel: +44 20 7107 8000 
 
 
 
 
About Tepnel Life Sciences plc 
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences 
products and services Group with two divisions, Molecular Diagnostics and 
Research Products & Services. The Company has laboratories, manufacturing and 
operations in the USA, UK and France with over 200 employees. Tepnel provides 
test kits, reagents and services to two highly synergistic markets, these being 
Molecular Diagnostics and Biomedical Research. The Company's strategy has been 
to identify high growth niche opportunities within these multi-billion pound 
markets. Tepnel focuses on these niche operations with internally developed 
products, patents, expertise and know-how as well as strategic acquisitions, to 
develop a leadership position within these defined market segments. For more 
information please visit www.tepnel.com. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 LISCKKKDABKDKND 
 

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024